Most Popular Reagents
Instruments
Antibodies
ELISA Kits
Protein Electrophoresis and Blotting
Protein and Antibody Purification
Recombinant Proteins
Molecular Biology
Stable Cell Lines
Cell Isolation and Activation
IVD Raw Materials
Therapy Applications
Resources
| $211.00 | |
| A02220-40 | |
|
|
|
|
|
|
|
|
|
| Ask us a question | |
| Specificity | This product is specific for Pertuzumab |
| Host Species | Rabbit |
| Immunogen | Pertuzumab F(ab')2 |
| Conjugate | Unconjugated |
| Working concentrations for specific applications should be determined by the investigators. The appropriate concentrations may be affected by secondary antibody affinity, antigen concentration, the sensitivity of the method of detection, temperature, the length of the incubations, and other factors. The suitability of this antibody for applications other than those listed below has not been determined. The following concentration ranges are recommended starting points for this product. | |||||
|
|||||
| Form | Lyophilized |
| Storage Buffer | Lyophilized with PBS, pH 7.2, containing 0.02% sodium azide. |
| Reconstitution | Reconstitute the lyophilized antibody with deionized water (or equivalent) to a final concentration of 0.5 mg/mL. |
| Storage Instructions | The lyophilized product remains stable for 1 year at -20℃ from the date of receipt. Upon reconstitution, it can be stored for 2-3 weeks at 2-8℃ or for 12 months at -20℃ or below. Avoid repeated freezing and thawing cycles. |
| Purification | Antigen affinity purification |
| Isotype | Rabbit IgG |
| Clonality | Polyclonal |
| Note | GenScript can customize this product per customer's request including product size, buffer components, etc. |
»
ELISA binding of Anti-Pertuzumab Antibody, pAb, Rabbit (GenScript, A02220) with Pertuzumab and Human IgG. Coating antigen: Ranibizumab and Human IgG, 1 µg/ml. Anti-Pertuzumab Antibody, pAb, Rabbit (GenScript, A02220) dilution start from 0.1 µg/ml. »
| Target Background | Pertuzumab (also called 2C4, trade name Perjeta) is a monoclonal antibody used in combination with trastuzumab and docetaxel for the treatment of metastatic HER2-positive breast cancer; it is also used in the same combination as a neoadjuvant in early HER2-positive breast cancer. The epitope for pertuzumab is the domain of HER2 where it binds to HER3, and pertuzumab prevents the HER2/HER3 dimer from forming, which in turn blocks signaling by the dimer and as a result prevents HER2 from functioning. |
| Synonyms | Perjeta, PERTUZUMAB, 2C4, 2C4 Antibody |
For laboratory research use only. Direct human use, including taking orally and injection and clinical use are forbidden.
